Abstract

EFFECTIVENESS OF BIOLOGICAL THERAPY IN RHEUMATOID ARTHRITIS

Dr. Fathia Ehmouda Zaid* and Dr. Sumeia Bozakouk

ABSTRACT

Our study was to estimate effectiveness of biological therapy in Rheumatoid arthritis by using predictor response of function score, disease activity, pain score. Patient and Method: Follow up study patients were diagnosed as rheumatoid arthritis (RA) Those patients were studied clinically and functional disability assessed by the Health Assessment Questionnaire (HAQ score) and the Disease Activity Score in 28 joints (DAS 28). Result: Ninthly three patients with diagnosed rheumatoid arthritis were included in the study. Patients clinical characteristics are The age of the study patients ranged from (24-68years), M=(48±13 year), 80 (86%)were female. the Mean DAS 28 activity at baseline was (4.4±1.2), the mean health assessment questionnaire score (HAQ)of patients(1.2). The management of rheumatoid arthritis be combined methotrexate with biological therapy was 40 (43%) of patient on Infliximab, 24(25.8%) of patient on Adalimumab, 19 (20.4%) of patient on Etarnercept and 10(10.7%) of patient on Rituximab. at follow-up. Mean DAS 28 activity at 6 months in patients was 1.2-3.6 M=(2.3±0.5), and Mean DAS 28 activity at 12 months in patients was 0.6-2.6 M=(1.2±0.4) with significant P value =0.000. Clinical improvement after biological therapy at 6 and 12 months measure by American College of Rheumatology (ACR) and improvement or EULAR Response with significant P value =0.000, in addition greater improvement in health assessment questionnaire score (HAQ) after biological therapy from baseline with significant P value =0.000 and improvement in pain score. Conclusion: The biologics therapy had effective decline disease activity in rheumatoid arthritis, improve function score and pain score and had significant benefits in outcomes for patients.

Keywords: Biological therapy - disease modified anti rheumatoid drugs(DMARDs) the Health Assessment Questionnaire (HAQ)- the Disease Activity Score in 28 joints (DAS 28)- rheumatoid factor (IgM-RF)- antibodies against citrullinated antigens (anti-CCP)- radiological